SM
CLDX icon

Sabby Management’s Celldex Therapeutics CLDX Stock Holding History

Sabby Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-73,094
Closed -$856K – 133
2020
Q2 		$950K Buy
+73,094
New +$324K 0.19% 47
2013
Q4 		– Sell
-2,132
Closed -$821K – 226
2013
Q3 		$1.13M Buy
+2,132
New +$731K 0.07% 115

Other funds holding CLDX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Sabby Management's CLDX Position: Q3 2020 in Review

Sabby Management sold out of Celldex Therapeutics (CLDX) in Q3 2020, closing a stake of 73,094 shares — an estimated $856K sold.

Sabby Management first reported a position in CLDX in Q3 2013 and held it in 2 quarters. The position peaked at $1.13M in Q3 2013. 91 funds tracked by Wall St. Rank hold CLDX as of Q3 2020.

  • Sabby Management reported no remaining Celldex Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Sabby Management sold 73,094 Celldex Therapeutics shares in Q3 2020, an estimated $856K.
  • Sabby Management first reported a position in Celldex Therapeutics in Q3 2013 and held it in 2 quarters.
  • Sabby Management's Celldex Therapeutics position peaked at $1.13M in Q3 2013.
  • 91 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2020.

Based on Sabby Management's 13F filing for Q3 2020, filed 16 Nov 2020.